Literature DB >> 3510915

Physiological and pharmacological evidence for the regulation of permeability.

G J Grega, S W Adamski, D E Dobbins.   

Abstract

Local intraarterial infusions of histamine-type mediators produce increases in microvascular pressure (Pmv), protein efflux, and net fluid filtration that promote edema formation. The rise in Pmv is not the primary determinant of edema formation inasmuch as mediator-stimulated edema formation develops without an increase in Pmv. The inflammatory mediators increase the hydraulic conductivity of the microvascular membrane as evidenced by a large increase in the capillary filtration coefficient (CFC) subsequent to an increase in permeability. The development of inflammatory edema is primarily attributable to the increase in protein efflux, which decreases the lymph-to-plasma total-protein ratio (L/P ratio), virtually eliminating the transmural colloid osmotic pressure gradient. Hence, fluid filtration is increased at almost any level of Pmv. Noninflammatory vasodilators and venous occlusion produce increases in Pmv and protein clearance, but fail to increase the L/P ratio. The increase in protein efflux and L/P ratio is attributable to a nonhemodynamic action of the inflammatory mediators, an increase in microvascular permeability to macromolecules. The increase in protein efflux, CFC, and net fluid filtration produced by various inflammatory mediators is largely inhibited by cooling, treatment with endothelial cell stabilizers, or perfusion with blood from hemorrhaged animals. This inhibition is independent of changes in hemodynamics and must be ascribed to a direct effect on the microvascular membrane, providing evidence for a variable macromolecular transport pathway. In contrast, increases in protein clearance produced by increasing Pmv are not inhibited by these maneuvers, which provides evidence for a static macromolecular transport pathway. These findings correlate well with those from microscopic studies supporting the concept that macromolecular permeability may be directly regulated at the level of the venular endothelial cell subsequent to the modulation of interendothelial cell junction gap size.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510915

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  20 in total

1.  Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.

Authors:  J G Filep; M G Sirois; A Rousseau; A Fournier; P Sirois
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

2.  Time-related changes in the Starling forces following extracorporeal circulation.

Authors:  K A Rein; R Stenseth; H O Myhre; O W Levang; S Kahn
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

3.  Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat.

Authors:  J G Filep; E Földes-Filep; A Rousseau; P Sirois; A Fournier
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

4.  The involvement of endothelial dysfunction, nitric oxide and prostanoids in the rat gastric microcirculatory responses to endothelin-1.

Authors:  J Lopez-Belmonte; B J Whittle
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Fluids reverse the early lipopolysaccharide-induced albumin leakage in rodent mesenteric venules.

Authors:  Peter B Anning; Simon J Finney; Suveer Singh; C Peter Winlove; Timothy W Evans
Journal:  Intensive Care Med       Date:  2004-07-16       Impact factor: 17.440

6.  Modulation by nitric oxide of platelet-activating factor-induced albumin extravasation in the conscious rat.

Authors:  J G Filep; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Nitric oxide modulates vascular permeability in the rat coronary circulation.

Authors:  J G Filep; E Földes-Filep; P Sirois
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

8.  Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors.

Authors:  J G Filep; M G Sirois; E Földes-Filep; A Rousseau; G E Plante; A Fournier; M Yano; P Sirois
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

9.  Effects of the ETA/ETB receptor antagonist, bosentan on endothelin-1-induced myocardial ischaemia and oedema in the rat.

Authors:  J G Filep; A Fournier; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

10.  Endothelin-1-induced myocardial ischaemia and oedema in the rat: involvement of the ETA receptor, platelet-activating factor and thromboxane A2.

Authors:  J G Filep; A Fournier; E Földes-Filep
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.